{"id":55523,"date":"2026-01-26T21:13:57","date_gmt":"2026-01-26T13:13:57","guid":{"rendered":"https:\/\/flcube.com\/?p=55523"},"modified":"2026-01-26T21:13:58","modified_gmt":"2026-01-26T13:13:58","slug":"huahui-healths-libevitug-wins-nmpa-approval-as-worlds-first-hdv-antibody-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55523","title":{"rendered":"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy"},"content":{"rendered":"\n<p><strong>Huahui Health<\/strong> announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>conditional approval<\/strong> for <strong>libevitug<\/strong>, a <strong>first\u2011in\u2011class antibody<\/strong> targeting the <strong>PreS1 region<\/strong> of hepatitis B and D viruses, for the treatment of <strong>chronic hepatitis D virus (HDV)<\/strong> infection in adults with or without compensated cirrhosis. The approval marks the <strong>world\u2019s first antibody\u2011based therapy<\/strong> for HDV and <strong>China\u2019s first treatment<\/strong> for this disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Huahui Health (China\u2011based)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Libevitug (anti\u2011PreS1 antibody)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Conditional marketing authorization<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic hepatitis D virus (HDV) infection in adults (with\/without compensated cirrhosis)<\/td><\/tr><tr><td><strong>Firsts<\/strong><\/td><td><strong>World\u2019s first<\/strong> antibody\u2011based HDV drug; <strong>China\u2019s first<\/strong> HDV treatment<\/td><\/tr><tr><td><strong>Clinical Program<\/strong><\/td><td>6\u2011year development; pivotal study HH003\u2011204 presented as <strong>Late\u2011Breaking<\/strong> at AASLD 2025<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>20\u202fJan\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>PreS1 region<\/strong> of hepatitis B surface antigen (HBsAg), blocking viral entry into hepatocytes and inhibiting both HBV and HDV replication<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Monoclonal antibody that <strong>neutralizes viral particles<\/strong> and <strong>prevents attachment<\/strong> to hepatocyte receptors, reducing viral load and liver inflammation<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First antibody to target the <strong>entry step<\/strong> of HDV lifecycle, offering a <strong>direct antiviral mechanism<\/strong> distinct from interferon\u2011based therapies<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Subcutaneous injection (dosing regimen per label)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-pivotal-study-hh003-204\">Clinical Evidence \u2013 Pivotal Study HH003\u2011204<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint (Week\u202f48)<\/th><th>Libevitug Response Rate<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Composite Response<\/strong> (virological + biochemical)<\/td><td><strong>44.1\u202f%<\/strong><\/td><td>Primary endpoint; superior to control<\/td><\/tr><tr><td><strong>HDV Virological Suppression<\/strong><\/td><td><strong>60\u202f%<\/strong><\/td><td>Significant viral load reduction<\/td><\/tr><tr><td><strong>ALT Normalization<\/strong><\/td><td><strong>70\u202f%<\/strong><\/td><td>Marker of reduced liver inflammation<\/td><\/tr><tr><td><strong>Liver Stiffness Improvement<\/strong><\/td><td>Significant and sustained<\/td><td>Indicates reduced fibrosis progression<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable tolerability; excellent safety<\/td><td>No new safety signals identified<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Design:<\/strong> Pivotal regulatory trial demonstrating <strong>superiority<\/strong> over control group across all core efficacy endpoints<\/li>\n\n\n\n<li><strong>Clinical Benefit:<\/strong> Sustained virological suppression and biochemical improvement with <strong>manageable safety profile<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>HDV\u2011Infected Patients<\/strong><\/td><td>12\u202fmillion<\/td><td>72\u202fmillion<\/td><\/tr><tr><td><strong>Diagnosed &amp; Treatment\u2011Eligible<\/strong><\/td><td>2.4\u202fmillion<\/td><td>14\u202fmillion<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Interferon\u2011alpha (limited efficacy, poor tolerability)<\/td><td><\/td><\/tr><tr><td><strong>Antibody Therapy Penetration<\/strong><\/td><td>0\u202f%<\/td><td>0\u202f%<\/td><\/tr><tr><td><strong>Annual Treatment Cost (USD)<\/strong><\/td><td>$15,000\u201120,000<\/td><td>$35,000\u201150,000<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>\u00a518\u202fbillion<\/td><td>$12\u202fbillion<\/td><\/tr><tr><td><strong>Libevitug Peak Share<\/strong><\/td><td>25\u202f%<\/td><td>8\u202f%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u00a54.5\u202fbillion<\/td><td>$960\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> HDV is the <strong>most severe form of chronic viral hepatitis<\/strong> with <strong>highest risk<\/strong> of cirrhosis and hepatocellular carcinoma; existing interferon therapies achieve <strong>&lt;30\u202f% sustained virological response<\/strong> with <strong>poor tolerability<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Libevitug offers <strong>targeted antibody therapy<\/strong> with <strong>superior efficacy<\/strong> (44\u201160\u202f% response rates) and <strong>better safety<\/strong> vs. interferon<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Conditional approval supports <strong>rolling submission<\/strong> to FDA and EMA; <strong>orphan drug designation<\/strong> expected given prevalence<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Huahui\u2019s <strong>Shanghai biologics facility<\/strong> (capacity 20,000\u202fL) will produce libevitug for China market; <strong>partnership discussions<\/strong> underway for global supply<\/li>\n\n\n\n<li><strong>Commercial Launch:<\/strong> Targeting <strong>tier\u20113 hepatology centers<\/strong> initially; <strong>NRDL negotiation<\/strong> planned for 2027 to expand access<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Validates <strong>PreS1 antibody platform<\/strong> for potential <strong>HBV functional cure<\/strong> combinations (with siRNA or capsid inhibitors)<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Conditional approval requires <strong>post\u2011marketing confirmatory study<\/strong>; full approval expected upon completion of 96\u2011week data<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, global regulatory submissions, and market penetration for libevitug. Actual results may differ due to competitive responses, pricing negotiations, and post\u2011marketing study outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Huahui Health announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional approval for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55525,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2198,15,89],"class_list":["post-55523","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-huahui-health","tag-product-approvals","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huahui Health announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional approval for libevitug, a first\u2011in\u2011class antibody targeting the PreS1 region of hepatitis B and D viruses, for the treatment of chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. The approval marks the world\u2019s first antibody\u2011based therapy for HDV and China\u2019s first treatment for this disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55523\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy\" \/>\n<meta property=\"og:description\" content=\"Huahui Health announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional approval for libevitug, a first\u2011in\u2011class antibody targeting the PreS1 region of hepatitis B and D viruses, for the treatment of chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. The approval marks the world\u2019s first antibody\u2011based therapy for HDV and China\u2019s first treatment for this disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55523\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:13:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T13:13:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy\",\"datePublished\":\"2026-01-26T13:13:57+00:00\",\"dateModified\":\"2026-01-26T13:13:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523\"},\"wordCount\":525,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2601.webp\",\"keywords\":[\"Huahui Health\",\"Product approvals\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55523#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55523\",\"name\":\"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2601.webp\",\"datePublished\":\"2026-01-26T13:13:57+00:00\",\"dateModified\":\"2026-01-26T13:13:58+00:00\",\"description\":\"Huahui Health announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional approval for libevitug, a first\u2011in\u2011class antibody targeting the PreS1 region of hepatitis B and D viruses, for the treatment of chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. The approval marks the world\u2019s first antibody\u2011based therapy for HDV and China\u2019s first treatment for this disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55523\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55523#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Huahui Health announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional approval for libevitug, a first\u2011in\u2011class antibody targeting the PreS1 region of hepatitis B and D viruses, for the treatment of chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. The approval marks the world\u2019s first antibody\u2011based therapy for HDV and China\u2019s first treatment for this disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55523","og_locale":"en_US","og_type":"article","og_title":"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy","og_description":"Huahui Health announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional approval for libevitug, a first\u2011in\u2011class antibody targeting the PreS1 region of hepatitis B and D viruses, for the treatment of chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. The approval marks the world\u2019s first antibody\u2011based therapy for HDV and China\u2019s first treatment for this disease.","og_url":"https:\/\/flcube.com\/?p=55523","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T13:13:57+00:00","article_modified_time":"2026-01-26T13:13:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55523#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55523"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy","datePublished":"2026-01-26T13:13:57+00:00","dateModified":"2026-01-26T13:13:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55523"},"wordCount":525,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55523#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2601.webp","keywords":["Huahui Health","Product approvals","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55523#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55523","url":"https:\/\/flcube.com\/?p=55523","name":"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55523#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55523#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2601.webp","datePublished":"2026-01-26T13:13:57+00:00","dateModified":"2026-01-26T13:13:58+00:00","description":"Huahui Health announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional approval for libevitug, a first\u2011in\u2011class antibody targeting the PreS1 region of hepatitis B and D viruses, for the treatment of chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. The approval marks the world\u2019s first antibody\u2011based therapy for HDV and China\u2019s first treatment for this disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55523#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55523"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55523#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2601.webp","width":1080,"height":608,"caption":"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55523#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huahui Health\u2019s Libevitug Wins NMPA Approval as World\u2019s First HDV Antibody Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55523"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55523\/revisions"}],"predecessor-version":[{"id":55526,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55523\/revisions\/55526"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55525"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}